Although Onc.Ads encoding GM-CSF have produced clinical benefits in patients with various malignancies (e.g., ovarian cancer, breast cancer, lung cancer) [62], GM-CSF also promotes the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs) in malignant glioma [77]. This evidence concerns the gene CSF2 and ovarian carcinoma.